On November 1, 2025, in Ho Chi Minh City, Naviva Group hosted a scientific conference themed “Advancements in Varicella Prevention Using the MAV/06 Strain.” The event aimed to update the latest scientific information and advances in the development of varicella vaccines based on the MAV/06 strain, while supporting healthcare professionals in accessing specialized knowledge for immunization practice.
Professional Updates on the MAV/06 Varicella Vaccine
At the conference, MSc., MD. Nguyen Hien Minh – Deputy Head of the Immunization Unit, University Medical Center Ho Chi Minh City presented the topic “Enhancing the Quality of Varicella Vaccines Derived from the MAV/06 Strain.” In the presentation, she emphasized the long development history and real-world usage data of the MAV/06 strain, a virus strain that has been deployed in South Korea since 1993 and incorporated into the National Expanded Programme on Immunization.
According to MSc., MD. Nguyen Hien Minh, first-generation varicella vaccines derived from the MAV/06 strain have been licensed in more than 30 countries, with over 30 million doses administered, including in Vietnam since 2008. Post-marketing surveillance data demonstrate consistent protective efficacy and a stable safety profile, providing a solid scientific foundation for the development of subsequent vaccine generations.
Building on this foundation, the second-generation MAV/06 varicella vaccine has been enhanced in terms of manufacturing technology, including the use of MRC-5 cell lines in accordance with World Health Organization (WHO) recommendations, an automated, fully closed production process, and a formulation free of antibiotics.
MSc., MD. Nguyen Hien Minh – Deputy Head of the Immunization Unit, University Medical Center Ho Chi Minh City
Providing additional perspectives from the distributor, Dr. Le Thi Hai Yen – Head of Training and Quality Control, Naviva Group shared professional insights into the development process of varicella vaccines based on the MAV/06 strain, while clarifying the key improvements of the second-generation vaccine, BARYCELA inj., in the context of international quality standardization.
Le Thi Hai Yen – Head of Training and Quality Management, Naviva Group
Naviva Group’s Direction in Infectious Disease Prevention
Speaking at the conference, Mr. Duong Van Minh – Southern Regional Sales Director, Naviva Group stated that the company is oriented toward strengthening the supply of infectious disease prevention solutions, including varicella, by ensuring a high-quality, stable vaccine supply aligned with the practical needs of Vietnam’s immunization system.
Mr. Duong Van Minh – Southern Regional Sales Director, Naviva Group
Immunization – An Effective and Sustainable Preventive Measure
The conference reaffirmed the role of proactive immunization in reducing disease risk, preventing complications, and limiting the spread of varicella within the community, particularly in school settings.
Through this academic activity, Naviva Group continues to affirm its role as the authorized distributor of the second-generation MAV/06 varicella vaccine – BARYCELA inj. – in Vietnam, working in partnership with healthcare facilities to enhance the quality and effectiveness of immunization programs.
